Biotech Deserves A Piece Of Every Dividend Growth Portfolio

Biotech Deserves A Piece Of Every Dividend Growth Portfolio


Taking into account their projected EPS growth rates and potential for dividend growth, both companies, but in particular Gilead Sciences, are attractively valued relative to the market. Amgen became a pioneer in the biotech world when it became the first large biotech stock to begin paying a regular dividend in 2011.



from Biotech News